Sharfstein On Zohydro: FDA Should Require Opioid Abuse Deterrent Standards
This article was originally published in The Pink Sheet Daily
Executive Summary
Former FDA Principal Deputy Commissioner Joshua Sharfstein suggests FDA create a pathway for development of new products for simultaneous treatment of chronic pain and opioid disorder.
You may also be interested in...
Abuse-Deterrent Opioids: FDA Regulatory Options Aired At Meeting
Brand industry favors two- to three-year period for withdrawal or reformulation of products without abuse-deterrent features, while generic industry calls for expedited review pathway. Purdue and Zogenix agree to waive three-year market exclusivity for their respective hydrocodone products.
Abuse-Deterrent Opioids: FDA Regulatory Options Aired At Meeting
Brand industry favors two- to three-year period for withdrawal or reformulation of products without abuse-deterrent features, while generic industry calls for expedited review pathway. Purdue and Zogenix agree to waive three-year market exclusivity for their respective hydrocodone products.
FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure
The departure of Principal Deputy Commissioner Joshua Sharfstein provides FDA an opportunity to take stock of its relationship with the new Congress and to re-evaluate its own organizational structure.